The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

The Effect of Proton Pump Inhibitors on Nutrition, Metabolism, Infection andSmall Intestinal Bacterial Overgrowth: Safe Perspective

영양, 대사 및 감염에 미치는 프로톤펌프억제제의 영향: Safe 측면

  • Kim, Jie-Hyun (Department of Internal Medicine, Institute of Gastroenterology, Gangnam Severance Hospital,Yonsei University College of Medicine)
  • 김지현 (연세대학교 의과대학 내과학교실)
  • Published : 2011.07.01
⟨ Previous Next ⟩

Abstract

Proton pump inhibitors (PPIs) have been widely used to treat patients with acid-related disorders because they are perceived to be safe and effective. However, they have the potential for side effects. Many studies have examined the side effects of long-term PPI exposure. We review the side effects of long-term PPIs, focusing on nutrition, metabolism, and infection.

Keywords

References

  1. Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology 2010;139:1115-1127. https://doi.org/10.1053/j.gastro.2010.08.023
  2. Kahrilas PJ, Shaheen NJ, Vaezi MF. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology 2008;135:1392-1413, 1413.e1-e5. https://doi.org/10.1053/j.gastro.2008.08.044
  3. Sharma VR, Brannon MA, Carloss EA. Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. South Med J 2004;97:887-889. https://doi.org/10.1097/01.SMJ.0000110405.63179.69
  4. den Elzen WP, Groeneveld Y, de Ruijter W, et al. Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals. Aliment Pharmacol Ther 2008;27:491-497. https://doi.org/10.1111/j.1365-2036.2008.03601.x
  5. Howden CW. Vitamin B12 levels during prolonged treatment with proton pump inhibitors. J Clin Gastroenterol 2000;30:29-33. https://doi.org/10.1097/00004836-200001000-00006
  6. Maton PN, Vinayek R, Frucht H, et al. Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study. Gastroenterology 1989;97:827-836.
  7. Mitchell SL, Rockwood K. The association between antiulcer medication and initiation of cobalamin replacement in older persons. J Clin Epidemiol 2001;54:531-534. https://doi.org/10.1016/S0895-4356(00)00340-1
  8. Ruscin JM, Page RL 2nd, Valuck RJ. Vitamin B(12) deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor. Ann Pharmacother 2002;36:812-816.
  9. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Atrophic gastritis during long-term omeprazole therapy affects serum vitamin B12 levels. Aliment Pharmacol Ther 1999;13:1343-1346. https://doi.org/10.1046/j.1365-2036.1999.00616.x
  10. Termanini B, Gibril F, Sutliff VE, Yu F, Venzon DJ, Jensen RT. Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med 1998;104:422-430. https://doi.org/10.1016/S0002-9343(98)00087-4
  11. Schenk BE, Festen HP, Kuipers EJ, Klinkenberg-Knol EC, Meuwissen SG. Effect of short- and long-term treatment with omeprazole on the absorption and serum levels of cobalamin. Aliment Pharmacol Ther 1996;10:541-545. https://doi.org/10.1046/j.1365-2036.1996.27169000.x
  12. Kapadia C. Cobalamin (Vitamin B12) deficiency: is it a problem for our aging population and is the problem compounded by drugs that inhibit gastric acid secretion? J Clin Gastroenterol 2000;30:4-6. https://doi.org/10.1097/00004836-200001000-00003
  13. Wolters M, Strohle A, Hahn A. Cobalamin: a critical vitamin in the elderly. Prev Med 2004;39:1256-1266. https://doi.org/10.1016/j.ypmed.2004.04.047
  14. Stewart CA, Termanini B, Sutliff VE, et al. Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment Pharmacol Ther 1998;12:83-98. https://doi.org/10.1046/j.1365-2036.1998.00274.x
  15. Koop H, Bachem MG. Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy. J Clin Gastroenterol 1992;14:288-292. https://doi.org/10.1097/00004836-199206000-00005
  16. Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 2006;355:1834-1836. https://doi.org/10.1056/NEJMc066308
  17. Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf) 2008;69:338-341. https://doi.org/10.1111/j.1365-2265.2008.03194.x
  18. Kuipers MT, Thang HD, Arntzenius AB. Hypomagnesaemia due to use of proton pump inhibitors: a review. Neth J Med 2009;67:169-172.
  19. Mackay JD, Bladon PT. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. QJM 2010;103:387-395. https://doi.org/10.1093/qjmed/hcq021
  20. Hoorn EJ, van der Hoek J, de Man RA, Kuipers EJ, Bolwerk C, Zietse R. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis 2010;56:112-116. https://doi.org/10.1053/j.ajkd.2009.11.019
  21. Richards JB, Goltzman D. Proton pump inhibitors: balancing the benefits and potential fracture risks. CMAJ 2008;179:306-307. https://doi.org/10.1503/cmaj.080873
  22. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008;179:319-326. https://doi.org/10.1503/cmaj.071330
  23. Geller JL, Adams JS. Proton pump inhibitor therapy and hip fracture risk. JAMA 2007;297:1429.
  24. Laine L. Proton pump inhibitors and bone fractures? Am J Gastroenterol 2009;104(Suppl 2):S21-S26.
  25. Thomson AB, Sauve MD, Kassam N, Kamitakahara H. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol 2010;16:2323-2330. https://doi.org/10.3748/wjg.v16.i19.2323
  26. Moayyedi P, Cranney A. Hip fracture and proton pump inhibitor therapy: balancing the evidence for benefit and harm. Am J Gastroenterol 2008;103:2428-2431. https://doi.org/10.1111/j.1572-0241.2008.02031.x
  27. Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 2010;139:93-101. https://doi.org/10.1053/j.gastro.2010.03.055
  28. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007;167:950-955. https://doi.org/10.1001/archinte.167.9.950
  29. Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008;149:391-398. https://doi.org/10.7326/0003-4819-149-6-200809160-00005
  30. Sultan N, Nazareno J, Gregor J. Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials. Can J Gastroenterol 2008;22:761-766.
  31. Yildizdas D, Yapicioglu H, Yilmaz HL. Occurrence of ventilatorassociated pneumonia in mechanically ventilated pediatric intensive care patients during stress ulcer prophylaxis with sucralfate, ranitidine, and omeprazole. J Crit Care 2002;17:240-245. https://doi.org/10.1053/jcrc.2002.36761
  32. Levy MJ, Seelig CB, Robinson NJ, Ranney JE. Comparison of omeprazole and ranitidine for stress ulcer prophylaxis. Dig Dis Sci 1997;42:1255-1259. https://doi.org/10.1023/A:1018810325370
  33. Kantorova I, Svoboda P, Scheer P, et al. Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial. Hepatogastroenterology 2004;51:757-761.
  34. Yamanaka Y, Mammoto T, Kita T, Kishi Y. A study of 13 patients with gastric tube in place after esophageal resection: use of omeprazole to decrease gastric acidity and volume. J Clin Anesth 2001;13:370-373. https://doi.org/10.1016/S0952-8180(01)00289-6
  35. Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol 2008;103:2308-2313. https://doi.org/10.1111/j.1572-0241.2008.01975.x
  36. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254-1260. https://doi.org/10.1086/496986
  37. Williams C, McColl KE. Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther 2006;23:3-10.
  38. Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 1996;39:54-59. https://doi.org/10.1136/gut.39.1.54
  39. Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2010;8:504-508. https://doi.org/10.1016/j.cgh.2009.12.022
  40. Theisen J, Nehra D, Citron D, et al. Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. J Gastrointest Surg 2000;4:50-54. https://doi.org/10.1016/S1091-255X(00)80032-3
  41. Lewis SJ, Franco S, Young G, O'Keefe SJ. Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther 1996;10:557-561. https://doi.org/10.1046/j.1365-2036.1996.d01-506.x
  42. Spiegel BM, Chey WD, Chang L. Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors? Am J Gastroenterol 2008;103:2972-2976. https://doi.org/10.1111/j.1572-0241.2008.01992.x